Investors | Indegene

Company Overview

We help biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way. We bring together healthcare domain expertise, fit-for-purpose technology, and an agile operating model to provide a diverse range of solutions. These aim to deliver, amongst other outcomes, a personalized, scalable and omnichannel experience for patients and physicians. It’s what drives our team and our purpose to enable healthcare organizations to be future ready.

Company Announcements

FY26-27 Q1

Latest Quarterly Reports

Press Release

Analyst Call Transcripts

Investor Presentation

Financial Results

Q1 FY26-27 Quarterly Results

₹ 10,631 M

Revenue

39.7%

YoY Revenue Growth

₹ 1,162 M

PAT

-0.2%

YoY PAT Growth

Clients with $1 Mn+ Revenue

5,826

Total Employees

29.0%

Healthcare Expertise

46.9%

Women Employees

Indegene is a new category

not a better version of an old one

E mbedded Revenue Partner

$77.1K

Revenue/Employee - Highest in Industry

Operate in clients' revenue-generating engine: Commercial & Med teams behind launches, brands & growth
Sit on growth-side budgets, not IT cost budgets; less exposed to cost-cutting cycles
Productivity-benefit gets redeployed as increased volume: personalized content and more channels

D eep Domain Expertise

29% +

Employees From Healthcare

With over 27 years of experience in life sciences, we are deeply integrated in client workflows
Manage critical workflows requiring high degree of domain expertise and regulatory compliance
Judgment-intensive work where GenAI compounds domain knowledge rather than replacing it

G enAI Disruptor

10+

Years of delivering AI

Pharma companies face complexity explosion (content volume & regulatory compliance) & fragmented non-standardized models resulting in efforts to centralize operations
Our AI-enabled solutions engage at enterprise level (not brand-by-brand) to re-engineer & re-imagine end-to-end processes, thus accelerating this transformation & taking wallet share from incumbents
GenAI price deflation pressures large incumbents but provides growth headroom for us at our current scale

E ngagement Model

~60%

Revenue* outcome-aligned

Global delivery model with multi-geography governance & standardization generating productivity at scale
Majority revenue is outcome-aligned — paid for work delivered and value created
Efficiency gains flow to the bottom line, creating incentive to adopt and scale newer technologies faster

*Revenue from Enterprise Contracts

Corporate Governance

Corporate Governance Policies Quarterly Compliance Report Other Documents CSR at Indegene Committees of the Board of Directors

Shareholder's Services

Distribution of Shareholding Related Party Transactions Annual General Meeting Postal Ballot

Quick Links